ArticleInfectious diseases and therapy2017
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.
Article in Infectious diseases and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pooled it
- A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.The Journal of infectious diseases · 2022Trial
- Review
- Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.Infectious diseases and therapy · 2026Review
- Article
- Hospitalizations Associated With Respiratory Syncytial Virus Illness Among Children and Adolescents in Ontario, Canada.Journal of the Pediatric Infectious Diseases Society · 2025Article
- Article
- A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization.Vaccines · 2024Article
- Maternal awareness, acceptability and willingness towards respiratory syncytial virus (RSV) vaccination during pregnancy in Ireland.Immunity, inflammation and disease · 2024Article
- The road to approved vaccines for respiratory syncytial virus.NPJ vaccines · 2023Review
- Case-control study of exclusive breast feeding and severe bronchiolitis in the United States.Paediatric and perinatal epidemiology · 2023Article
- Content validation of a caregiver diary to monitor severity and recovery of pediatric patients with respiratory syncytial virus infection.Journal of patient-reported outcomes · 2022Article
- Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).The Journal of infectious diseases · 2022Observational
- Review
- Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types.Frontiers in immunology · 2019Article
- Respiratory syncytial virüs infections in neonates and infants.Turk pediatri arsivi · 2018Review
- Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.BMC health services research · 2018Article
- Respiratory syncytial virus seasonality and its implications on prevention strategies.Human vaccines & immunotherapeutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRespiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States, and the risk for RSV hospitalizations is greater for infants born preterm. Recent studies in preterm and term infants have shown that RSV hospitalization rates vary considerably depending on infant chronologic age. This study sought to aggregate the data available from published literature and from nationally representative databases of US infant hospitalizations to generate a composite description of the effect of young chronologic age on RSV hospitalizations among US preterm and term infants by individual month of age.
methodsData describing the relative incidence of RSV hospitalizations by individual month of chronologic age during the first year of life were obtained from recently published studies, the 2006-2011 National Inpatient Sample databases, and the 2006 and 2009 Kids Inpatient Databases.
resultsAll data sources showed that ≥20% of infant RSV hospitalizations occurred in the second month of life and >50% and >75% of RSV hospitalizations were observed during the first 3 and 6 months of life, respectively. These findings were consistent for both preterm and term infants.
conclusionData from multiple sources demonstrate that the greatest risk of RSV hospitalization occurs during the first 6 months of life among US preterm and term infants. Strategies to prevent infant RSV hospitalizations should be targeted to infants during the first months of life.
fundingAstraZeneca.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.